Rapamycin and the Dog Aging Project explained

This is the study most people mean when they ask whether rapamycin "works" in dogs. Here is what it is actually testing, why dogs are such a useful model, and how to read its status honestly. For the broader canine picture, see our overview of rapamycin for dogs.

What is the Dog Aging Project testing?

The Dog Aging Project is a large, long-running study of ageing in ordinary pet dogs, and its rapamycin arm is the TRIAD trial — a placebo-controlled test of low-dose rapamycin in older companion dogs, tracking healthspan, lifespan and cardiac outcomes.^[1] Because it follows dogs living normal lives, it is designed to answer a real-world question, not just a laboratory one.

Why are dogs such a good ageing model?

Dogs are unusually well suited to this kind of research. They share our homes and environment, develop many of the same age-related diseases, and age several times faster than we do — so a genuine anti-ageing effect should appear sooner and more clearly than in a decades-long human study.^[3] That combination of shared biology and a faster clock is exactly what makes them valuable.

Promising model · results still pending

What is the current status, honestly?

The research is ongoing, not finished. It has not established rapamycin as a proven anti-ageing treatment for dogs, and specific enrolment numbers, doses and outcomes should be checked against the project's own current publications rather than summarised secondhand. Treat it as one of the most watched tests in the field — not as a settled result or a consumer product.

What it means for dog owners

An ongoing trial is not a green light to dose your own dog. Rapamycin is a potent prescription immunosuppressant, and canine longevity dosing is still being worked out under controlled conditions — inside a double-masked, placebo-controlled, multicentre protocol with veterinary oversight at every site.^[2] The appropriate route is a conversation with your own veterinarian, ideally exploring legitimate study participation.

Where this fits

The dog work matters partly because it may inform the human question too. If low-dose rapamycin shows a clear healthspan signal in dogs, it strengthens the case for the same drug in people — which is the thread we follow in the main rapamycin evidence guide and across the Rapamycin.store library.

Frequently asked questions

What is the Dog Aging Project?

The Dog Aging Project is a large, long-term study of ageing in companion dogs living in ordinary homes. Its rapamycin arm, the TRIAD trial, is a placebo-controlled study testing whether low-dose rapamycin improves healthspan, lifespan and heart function in pet dogs.

What is the TRIAD trial testing?

TRIAD (Test of Rapamycin In Aging Dogs) is a placebo-controlled trial of low-dose rapamycin in older companion dogs. It looks at outcomes like healthspan, lifespan and cardiac measures under veterinary supervision.

Why are dogs a good model for ageing?

Pet dogs share our homes and environment, develop many of the same age-related diseases, and age faster than we do, so effects show up sooner. Because they live real lives rather than lab conditions, results are more externally valid than rodent studies.

Can I give my dog rapamycin now?

Not on your own. Rapamycin for canine ageing is still experimental and unproven as a consumer treatment. Any use belongs with your veterinarian, and ideally through legitimate study participation rather than off-label self-dosing.

Has the Dog Aging Project proven rapamycin works?

No. The research is ongoing and has not established rapamycin as a proven anti-ageing treatment for dogs. Specific enrolment numbers, doses and results should be checked against the project's own current publications.